Want to see FR:TNG full AI Analyst Report?
TNG Stock Chart & Stats
€0.72
>-€0.01(-0.41%)
At close: 4:00 PM EDT
€0.72
>-€0.01(-0.41%)
Day’s Range― - ―
52-Week Range€0.72 - €1.50
Previous CloseN/A
Volume24.07K
Average Volume (3M)129.86K
Market Cap
€200.64M
Enterprise Value€103.55M
Total Cash (Recent Filing)€111.86M
Total Debt (Recent Filing)€2.06M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding278,559,940
10 Day Avg. Volume204,663
30 Day Avg. Volume129,863
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)1.14
Price to Sales (P/S)282.76
P/FCF Ratio-3.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€8.15M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt relative to equity gives the company financial flexibility to fund clinical development and absorb R&D setbacks without immediate refinancing pressure. Over a 2-6 month horizon this reduces short-term insolvency risk and supports program continuity while trials progress.
Specialized Immunotherapy R&D FocusA clear focus on therapeutic vaccines and individualized/viral-vector immunotherapies aligns with durable oncology trends favoring immune- and precision-based treatments. This specialization concentrates R&D expertise and makes meaningful clinical readouts and partnerships the primary long-term value drivers.
Partnership-driven Revenue ModelReliance on collaborations, upfront payments and milestone/royalty streams provides non-product funding that can support development without immediate commercialization. Structurally, partner funding can de-risk programs, provide validation, and extend runway if agreements continue to deliver cash.
Bears Say
High And Persistent Cash BurnConsistent negative operating and free cash flow indicates the business consumes cash to fund ongoing R&D. This structural cash consumption requires regular external financing or partner payments, increasing dilution or funding risk and potentially constraining trial timelines or program spend.
Collapsed Revenue And Negative MarginsA near-total revenue collapse combined with deeply negative EBIT and net margins shows the company lacks sustainable product revenues and that costs far exceed sales. Structurally this prolongs dependency on external capital and delays any credible path to operating profitability absent new revenue streams.
Funding Dependence And Dilution RiskThe balance sheet commentary flags fluctuating equity levels and funding dependence, a common issue in clinical-stage biotech. Structurally, this elevates the probability of future equity raises or dilutive financings, which can disrupt long-term ownership economics and slow program execution if market access tightens.
Transgene News
TNG FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest stock price was €0.72 and its highest was €1.50 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €200.64M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Sep 24, 2026 which is in 57 days.
How were Transgene SA’s earnings last quarter?
Currently, no data Available
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA does not currently pay dividends.
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 278,559,940 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in FR:TNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Transgene SA
Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―